Bodo_Spori_small.jpg
Domainex Ltd, a privately-owned drug discovery services company, has announced the appointment of Dr Bodo Spori as Head of Business Development for Europ.
brianlarkin_small.png

SP Industries Inc. has announced the appointment of Brian Larkin as its President and Chief Executive Officer effective February 19th, replacing William (Bill) Downs who recently retired. 

david_colpman.jpg

Forendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, today announces the appointment of David Colpman as a non-executive director to its Board of Directors.

jamiemacdonaldparexel.jpg

Company Co-founder Josef von Rickenbach to retire after 35 years of leadership; serve as Chairman of the Board.

© SOTIO

SOTIO, a biotechnology company belonging to the PPF Group, announces today the appointment of Professor Radek Špíšek as Chief Executive Officer.

Picture ©Mission Therapeutics

Today Mission Therapeutics, a drug discovery and development company focused on treating fibrosis, neurodegenerative and other diseases by selectively targeting deubiquitylating enzymes (DUBs), announced the promotion of Dr Paul Thompson to Vice President, Clinical Development with immediate effect.

EB-federico_pollano_app.jpg

Rentschler Biopharma SE, a service provider for biopharmaceuticals, today announced the appointment of Mr. Federico Pollano as the new Senior Vice President of Business Development, effective March 1.

© Lukasz Kobus, European Union, 2018

Paquet is a French national who since November 2015 has served as one of the three Deputy Secretaries-General of the Juncker Commission, and has now been been appointed as Director General of DG Research and Innovation

Wills-Hughes-Wilson.jpg

Mereo BioPharma Group plc, a multi-asset biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases, today announced the appointment of Wills Hughes-Wilson as Head of Patient Access and Commercial Planning.

Image © Hikma Pharmaceuticals

Hikma Pharmaceuticals today announces its Board of Directors has appointed Sigurdur (Siggi) Olafsson as Chief Executive Officer. Mr Olafsson will also join Hikma’s Board of Directors as an executive director, subject to election at the next annual general meeting in May 2018.